Deepak Bhatt, MD, MPH, MBA, spoke to Cardiovascular Business about the growing importance of evaluating coronary inflammation in heart patients. There has been an explosion of interest in this area since the FDA's 2023 clearance of colchicine.
Hadley Wilson, MD, spoke to Cardiovascular Business at the three-day event to discuss key late-breaking studies and trends. Topics included new drug treatments, AI and much more.
Gilbert Tang, MD, spoke to Cardiovascular Business about late-breaking data from the TRILUMINATE IDE trial. While early results were promising, these latest findings highlight the TriClip device's true value for the first time.
A team of specialists from Cleveland Clinic reviewed nearly 3,000 medications, writing that a common type 2 diabetes medication offered the most potential as an effective treatment for AFib.
A well-known cardiologist who once fully supported COVID-19 vaccines is now saying he thinks they have done more harm than good. Online, as one might expect, people on both sides of this particular debate have been quick to respond.
Researchers have received a five-year grant worth $30 million to study how a new-look physical rehab program impacts outcomes among older HFpEF patients.
Diabetes and atrial fibrillation are just some of the factors that can increase a patient's risk of being hospitalized for heart failure within one year of undergoing a successful TAVR procedure.
Could wearables help AFib patients take fewer blood-thinning medications and reduce their risk of stroke? The team behind a new seven-year analysis hopes to find out.
Researchers have shared an updated analysis of the SMART-CHOICE study, focusing on major adverse cardiac and cerebrovascular events—as well as bleeding events—among PCI patients after three years.
Two-year outcomes of a QFR-guided vessel and lesion selection strategy showed that the benefits of QFR guidance continued to accrue over time compared with standard angiography guidance in patients undergoing PCI.
Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.
